- Based on preliminary financial information, and subject to year-end closing adjustments, PyroGenesis expects revenue for the fourth quarter 2020 to be between $3 – $5 million, resulting in total revenues for the fiscal year ending 2020 of approximately $14 – $16 million, as compared to $1.07 million (Q4 2019) and $4.8 million (FY 2019), respectively.
- Company also expects earnings per share for the fourth quarter to be in the range of $0.10 – $0.12, and for the fiscal year ending 2020 of between $0.22 – $0.24 , as compared to a loss of $0.04 (Q4 2019) and a loss of $0.07 (FY 2020), respectively.
MONTREAL, Jan. 11, 2021 — PyroGenesis Canada Inc. ( http://www.pyrogenesis.com ) (TSX: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to provide guidance for the fourth quarter, and full year, both ending December 31 st , 2020.
Based on preliminary financial information, and subject to year-end closing adjustments, PyroGenesis expects revenue for the fourth quarter 2020 to be between $3 – $5 million, resulting in total revenues for the fiscal year ending 2020 of approximately $14 – $16 million, as compared to $1.07 million (Q4 2019) and $4.8 million (FY 2019), respectively.
The Company also expects earnings per share (“EPS”) for the fourth quarter to be in the range of $0.10 – $0.12, and for the fiscal year ending 2020 of between $0.22 – $0.24 , as compared to a loss of $0.04 (Q4 2019) and a loss of $0.07 (FY 2020), respectively.
The Q4 2020 guidance and actual 2019 results noted above are summarized in the following table below:
| Actual 2019 | Guidance 2020 | |
| Revenue | ||
| Q4 | $1.07 MM | $ 14-16 MM |
| YE | $4.8 MM | $ 22-24 MM |
| EPS Basic | ||
| Q4 | ($0.04) | $0.10-$0.12 |
| YE | ($0.07) | $0.22-$0.24 |
Tags: 3D Systems Corporation, drosrite, Northrop Grumman Corporation, plasma, plasma torch, powders, PUREVAP